CD19 and acute lymphoblastic leukemia: BAFF‐R CAR T cells have been methodically engineered and characterized in various in vitro assays, specifically exhibiting cytotoxic efficacy in xenograft models of R/R acute lymphoblastic leukemia (R/R ALL) with CD19 antigen loss.34, 35